Orphan products - pain relief for clinical development headaches

被引：13

作者：

Milne, CP ^{[1
]}

机构：

[1] Tufts Univ, Tufts Ctr Study Drug Dev, Concord, NH 03301 USA

来源：

NATURE BIOTECHNOLOGY | 2002年 / 20卷 / 08期

关键词：

D O I：

10.1038/nbt0802-780

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

As the cost of clinical development rises, and products take longer to reach the market, the biotechnology industry may be wise to take a closer look at orphan drug indications.

引用

页码：780 / 784

页数：5

共 27 条

[1]

ARLINGTON S, 2000, PHARM EXEC JAN, P74

[2]

ASHTON G, 2001, NAT BIOTECHNOL, V3

[3] RESEARCH-AND-DEVELOPMENT COSTS FOR NEW DRUGS BY THERAPEUTIC CATEGORY - A STUDY OF THE UNITED-STATES PHARMACEUTICAL-INDUSTRY [J].

DIMASI, JA ;

HANSEN, RW ;

GRABOWSKI, HG ;

LASAGNA, L .

PHARMACOECONOMICS, 1995, 7 (02) :152-169

[4]

ENGEL S, 2002, R D DIRECTIONS APR, P38

[5] The distribution of sales revenues from pharmaceutical innovation [J].

Grabowski, HG ;

Vernon, J .

PHARMACOECONOMICS, 2000, 18 (Suppl 1) :21-32

[6]

HAAN K, 2002, BIOCENTURY BERNSTEIN, V10

[7] Health spending projections for 2001-2011: The latest outlook [J].

Heffler, S ;

Smith, S ;

Won, G ;

Clemens, MK ;

Keehan, S ;

Zezza, M .

HEALTH AFFAIRS, 2002, 21 (02) :207-218

[8] Realism in drug discovery - could Cassandra he right? [J].

Horrobin, DE .

NATURE BIOTECHNOLOGY, 2001, 19 (12) :1099-1100

[9]

KAITIN KI, 2002, TUFTS CTR STUDY DRUG, V4

[10]

Marshall E, 2000, SCIENCE, V288, P1715

← 1 2 3 →